Scynexis (SCYX) Amortizatization of Intangibles (2016 - 2026)
Scynexis (SCYX) posted Amortizatization of Intangibles of $41000.0 for Q1 2026, down 33.87% on a QoQ basis from $62000.0 in Q4 2025, and down 79.4% year-over-year from $199000.0 in Q1 2025.
Scynexis (SCYX) Amortizatization of Intangibles (2016 - 2026) Analysis & Trends
Scynexis' Amortizatization of Intangibles history runs 8 years deep, the most recent figure standing at $41000.0 for Q1 2026.
- Quarterly Amortizatization of Intangibles fell 79.4% year-over-year to $41000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $316000.0 (down 75.43% YoY) and the FY2025 annual result came in at $474000.0, down 64.63% from the prior year.
- Amortizatization of Intangibles was $41000.0 for Q1 2026 at Scynexis, down from $62000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $802000.0 in Q3 2023 and bottomed at -$319000.0 in Q2 2023.
- A 5-year average of $233600.0 and a median of $219000.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles surged 791.11% — and 2025, when it plunged 79.41%.
- Scynexis' Amortizatization of Intangibles stood at $219000.0 in 2022, then surged by 191.32% to $638000.0 in 2023, then sank by 61.91% to $243000.0 in 2024, then plunged by 74.49% to $62000.0 in 2025, then slumped by 33.87% to $41000.0 in 2026.
- Business Quant data shows SCYX's Amortizatization of Intangibles at $41000.0 in Q1 2026, $62000.0 in Q4 2025, and $98000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Scynexis | 23.19 Mn | -13.57 Mn | - | 41,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41,000.00 |
| Mar 31, 2026 | 41,000.00 |
| Dec 31, 2025 | 62,000.00 |
| Dec 31, 2025 | 62,000.00 |
| Sep 30, 2025 | 98,000.00 |
| Sep 30, 2025 | 98,000.00 |
| Jun 30, 2025 | 115,000.00 |
| Jun 30, 2025 | 115,000.00 |
| Mar 31, 2025 | 199,000.00 |
| Mar 31, 2025 | 199,000.00 |
| Dec 31, 2024 | 243,000.00 |
| Dec 31, 2024 | 243,000.00 |
| Sep 30, 2024 | 476,000.00 |
| Sep 30, 2024 | 476,000.00 |
| Jun 30, 2024 | 368,000.00 |
| Jun 30, 2024 | 368,000.00 |
| Mar 31, 2024 | 253,000.00 |
| Mar 31, 2024 | 253,000.00 |
| Dec 31, 2023 | 638,000.00 |
| Dec 31, 2023 | 638,000.00 |